NMN, NR and the Longevity Gold Rush; What the Human Trials Actually Show

The NAD+ supplement market is worth billions of dollars and is built on a specific chain of reasoning: NAD+ levels fall as we age, animal studies show that restoring them extends healthy lifespan, and therefore taking a precursor molecule like NMN or nicotinamide riboside should slow aging in humans. That chain may turn out to be partially correct. But the human evidence — which is the only evidence that matters for what you actually put in your body — tells a more complicated version of the story. This episode works through what the clinical trials have actually measured, where the data holds up, where it doesn't, and what a regulatory dispute with the FDA reveals about how this whole category came to market. Start with the biochemistry, because without it the trial results don't make sense. NAD+, nicotinamide adenine dinucleotide, is a coenzyme present in every cell in your body. It sits at the center of energy metabolism — it's essential for the mitochondria to convert food into usable energy — and it also activates a class of proteins called sirtuins, which are involved in DNA repair and stress response. NAD+ concentrations measurably decline with age. By middle age, human tissue NAD+ levels are substantially lower than in young adults, though the exact magnitude varies by tissue and by how you measure it. The research consensus on the decline itself is solid. What's contested is what that decline causes, and whether reversing it does anything useful. NMN, nicotinamide mononucleotide, and NR, nicotinamide riboside, are both molecules the body can convert into NAD+. They're not identical chemically, but they share the same destination. The question the supplement industry answered before the clinical data did was whether oral supplementation with these molecules actually raises NAD+ in humans, and whether that rise translates into anything clinically meaningful. On the first part of that question, the answer is fairly clear. NMN taken orally does raise circulating NAD+ levels. This has been replicated across multiple trials. A 2025 meta-analysis by Zhang and colleagues, published in Critical Reviews in Food Science and Nutrition, pooled twelve randomized controlled trials involving 513 participants and confirmed consistent NAD+ elevation. The same year, a head-to-head trial by Christen and colleagues, published in Nature Metabolism, directly compared NMN, nicotinamide riboside, and plain nicotinamide — the cheapest and most widely available form of vitamin B3 — over 14 days. NMN and NR both roughly doubled circulating NAD+ levels. Nicotinamide had no significant effect. That result matters because nicotinamide is far cheaper than either NMN or NR, so it tells you something about what you're actually paying for. Separately, a trial using a pharmaceutical-grade NMN formulation called MIB-626, dosed at two grams per day for 14 days, found significant increases in both blood NAD+ and its downstream metabolites, with no measurable impact on kidney function. That trial adds to confidence that high doses are biochemically active and don't appear to cause immediate organ stress. The biochemical signal is real. You take NMN or NR, your blood NAD+ goes up. The harder question is what happens after that. The clinical outcomes are where the picture gets genuinely complicated. The 17 completed human trials catalogued since 2020 have looked at a range of endpoints: muscle function, physical endurance, metabolic markers, cardiovascular parameters, sleep quality. Some trials report improvements. Others don't. Yi and colleagues, in a 2023 multicenter randomized controlled trial published in GeroScience, enrolled 80 adults and tested doses between 300 and 900 milligrams per day over 60 days. They found no serious adverse events and reported improved physical endurance. That's a positive signal. But a separate 24-week trial in older diabetic men found that NMN supplementation was safe and did raise NAD+, but failed to improve grip strength or walking speed — two of the most clinically meaningful markers of physical function in aging adults. Those two trials aren't necessarily contradictory, because the populations, doses, and outcome measures differ. But they illustrate the core problem: there is no consistent, replicated evidence that raising blood NAD+ with NMN or NR produces a specific, reliable clinical benefit in humans. This is not a small caveat. It's the central limitation of the current evidence base. The mechanism is plausible, the animal data is genuinely impressive, the biochemical target is real. But going from "blood NAD+ went up" to "this slows aging" requires a chain of inference that the human trials haven't yet closed. There's also a measurement problem that runs through most of this research. The majority of trials measured NAD+ in blood — specifically in peripheral blood mononuclear cells or plasma. Blood is easy to sample. But the tissues where NAD+ decline is thought to matter most — skeletal muscle, the brain, the liver — are not easily sampled in living humans. The GeroScience paper from Springer notes that oral NMN is absorbed and converted to NAD+ in blood fairly quickly, but the relationship between circulating NAD+ and intracellular NAD+ in target tissues remains unclear. There's also emerging evidence that gut microbial conversion plays a role in how both NMN and NR raise NAD+, with some data suggesting that gut bacteria convert these molecules to nicotinic acid as an intermediate step. If that's correct, it raises genuine questions about whether the specific molecular form you're taking — NMN versus NR versus something else — is as important as the supplement marketing suggests. The endpoint most trials are measuring, blood NAD+, may not be the endpoint that actually matters for aging biology. The safety data is the area where the clinical record is most consistently reassuring. The Zhang meta-analysis across 12 trials and 513 participants found zero serious adverse events. The most commonly reported side effects are mild gastrointestinal discomfort, occurring in roughly 8 to 12 percent of participants, headache in 3 to 5 percent, and flushing in 2 to 4 percent — all at rates statistically indistinguishable from placebo. Igarashi and colleagues ran what was at the time the longest trial in older adults: 250 milligrams per day for 12 weeks in 42 men over 65. No adverse events. The Yi GeroScience trial across doses up to 900 milligrams per day in 80 adults confirmed tolerability. The MIB-626 trial at 2 grams per day showed no kidney impact over 14 days. That's a reasonably consistent safety picture at doses up to 1,250 milligrams per day over periods up to about 12 weeks. Eric Verdin, an immunologist and longevity researcher, has publicly flagged what the data doesn't yet address: what happens with continuous use beyond 12 weeks, particularly at higher doses. The longest single trial in this dataset ran 12 weeks. A 24-week trial exists but involved a specific older diabetic population. No one has run a year-long safety trial in otherwise healthy adults. That gap is real, and the field acknowledges it. The structural limitation of the evidence base is straightforward. The Zhang meta-analysis pooled just 513 participants across 12 trials. By comparison, a Phase 3 pharmaceutical trial for a drug intended to treat a common condition typically enrolls thousands of participants across multiple sites. Seventeen completed human trials sounds like a substantial evidence base until you consider that most of them ran for 8 to 12 weeks, enrolled fewer than 100 participants each, and measured different outcomes, making it difficult to pool results meaningfully. This is the science progressing, not the science concluded. Which brings us to the regulatory situation, which has created a specific kind of confusion in this market. Under U.S. law, if a substance has been investigated as a drug ingredient — meaning a company has filed an Investigational New Drug application for it — then it can potentially be excluded from sale as a dietary supplement. In late 2022, the FDA sent a warning letter to at least one NMN supplement seller, and for a period in 2023 the agency appeared to be moving toward excluding NMN from the supplement category on the grounds that it had been investigated as a drug. NMN continues to be sold legally as a dietary supplement as of the time this episode was recorded, but the regulatory status is not fully resolved. The FDA has not issued a final rule. What this episode in regulatory history reveals is worth understanding clearly: NMN was brought to market as a supplement, scaled into a major consumer category, and sold to millions of people before the human clinical trial evidence was in place to support the claims being made about it. The regulatory question isn't just about paperwork. It reflects the fact that the usual sequence — establish the evidence, then sell the product — ran in reverse here. The NMN versus NR versus nicotinamide question has direct implications for how people spend money. The Christen 2025 Nature Metabolism trial is the most direct comparison available. NMN and NR performed comparably as NAD+ boosters. Nicotinamide did not. NMN typically retails for considerably more than NR, and NR costs more than plain nicotinamide. If the goal is simply to raise circulating NAD+, the head-to-head data does not currently support the premium pricing of NMN over NR. Whether NMN offers advantages the blood NAD+ measurements aren't capturing — tissue-specific effects, different metabolite profiles, different downstream biology — is a legitimate scientific question, but it's an open one. It is not settled in favor of NMN at this point. So here is what the trial record actually shows. NAD+ does decline with age. NMN and NR do raise circulating NAD+ in humans. The safety profile at tested doses over tested durations is consistently clean. These are not trivial findings. But the gap between "raises blood NAD+" and "produces meaningful clinical benefits in aging humans" has not been bridged by the current trial record. Some trials show functional improvements. Others, including longer and more targeted ones, don't. That outcome heterogeneity isn't noise to be dismissed — it reflects genuine uncertainty about what, if anything, NAD+ precursor supplementation does for human health beyond the biomarker. The trial record that exists — 17 human studies, mostly 8 to 12 weeks, mostly under 100 participants, measuring different endpoints — is the beginning of a clinical evidence base, not the end of one. The open questions are substantial: whether blood NAD+ elevation reflects what's happening in the tissues that matter for aging; whether any clinical benefit is durable beyond the trial window; what the long-term safety profile looks like; whether nicotinamide riboside is equivalent to the more expensive NMN; and what the FDA's final regulatory position will mean for how these products are sold and labeled. The NAD+ supplement market made promises ahead of the evidence. The evidence, as it accumulates, is confirming the biochemical premise while leaving the clinical promise largely unverified. That gap is the central fact about this category, and it remains open.